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Abstract: Marine fungi represent a huge potential for new natural products and an increased number
of new metabolites have become known over the past years, while much of the hidden potential still
needs to be uncovered. Representative examples of biodiversity studies of marine fungi and of natural
products from a diverse selection of marine fungi from the author’s lab are highlighting important
aspects of this research. If one considers the huge phylogenetic diversity of marine fungi and their
almost ubiquitous distribution, and realizes that most of the published work on secondary metabolites
of marine fungi has focused on just a few genera, strictly speaking Penicillium, Aspergillus and maybe
also Fusarium and Cladosporium, the diversity of marine fungi is not adequately represented in
investigations on their secondary metabolites and the less studied species deserve special attention.
In addition to results on recently discovered new secondary metabolites of Penicillium species, the
diversity of fungi in selected marine habitats is highlighted and examples of groups of secondary
metabolites produced by representatives of a variety of different genera and their bioactivities are
presented. Special focus is given to the production of groups of derivatives of metabolites by the
fungi and to significant differences in biological activities due to small structural changes.
Keywords: marine fungi; marine natural products; Tethya aurantium; biological activities; fungal diversity
1. Introduction
For many years the study of marine fungi has been largely neglected for several reasons. One of
the reasons may be related to the low abundance of fungi in the marine environment and a second with
the doubt of the existence of true marine fungi. This has changed in recent years due to the recognition
that marine fungi represent a quite diverse group and an excellent source of natural products. Despite
the fact that many fungi are cosmopolitan and live as well in the sea as in other soil and freshwater
habitats, in a number of cases we have obtained evidence that under the conditions of the marine
environment, i.e., in the presence of marine salts, a different metabolite profile is produced by fungi
as compared to the fresh water situation [1–3]. This observation fits well with the general findings
that changing the growth conditions is a good tool to promote the production of metabolites not seen
under standard culture conditions. In addition to these cosmopolitan marine isolates, a group of true
marine fungi exists that comprises a number of genera so far exclusively found in marine habitats.
Cultivation-dependent studies demonstrated that marine macroorganisms, such as sponges and
algae, are a rich source for fungi [2,4–7]. Even in deep-sea hydrothermal ecosystems, an unsuspected
high diversity of fungal species was found using molecular approaches [8]. In consequence of this
recognition, in recent years, an increasing number of new natural products have been characterized
from marine fungi and there is no doubt that they produce a large number of interesting secondary
metabolites, which often show pharmaceutically relevant bioactivities and may be candidates for the
development of new drugs. By the end of the year 1992 only 15 fungal metabolites were reported [9]
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and approximately 270 compounds were described until 2002 [7]. In the period from 2000 to 2005,
approximately 100 new marine fungal metabolites were listed [10] and this number increased to 690
in the period from 2006 until 2010 [6]. This trend still continues and members of the fungal genera
Penicillium and Aspergillus were major objects in this field and they produced most of the described
new compounds as depicted in recent reviews on this topic, e.g., by Blunt et al. [11]. However, the
diversity of fungi in marine environments is by far not adequately represented in these studies on
marine natural products. Though bioactivities of secondary metabolites from marine fungi reveal
interesting levels for a number of clinical relevant targets, they are not well represented in the pipelines
of drugs and none of them currently is on the market [12].
Therefore, we have put emphasis on the analysis of the fungal diversity of selected habitats and
on the evaluation of the secondary metabolite production of a phylogenetically diverse selection of
fungi from different marine environments. The overall goal was to reach out from the marine habitat to
the candidate for drug development, as far as is possible in a research laboratory. The general strategy
was to determine the cultured biodiversity and to translate this to the chemical diversity of natural
products and to enforce biotechnological production of top candidates as outlined by Imhoff et al. [12].
An important aspect of this strategy is the use of a wide range of media and growth conditions to
increase the cultured diversity of fungi, but also the variation of culture conditions for the isolates to
improve the spectrum and the yield of produced metabolites. In addition, the following steps were of
relevance for the success of this strategy: the identification of the isolates based on morphology and
genetic sequence information as far as possible; the preservation of pure cultures in a strain collection,
the extraction; dereplication, purification; identification and preservation in a physical substance
library of secondary metabolites; the application of a wide range of bioactivity assays to the substances;
and, if appropriate, the identification of chemical structures and improvement of their production by
biotechnological methods [12].
The present report gives a personal view on work of marine fungi and their natural products of the
authors group during the past 10 years and by no means attempts to give a comprehensive overview.
Representative examples of biodiversity studies of marine fungi and of secondary metabolites
produced by a diverse selection of marine fungi highlight major aspects of this research.
Our studies started up with interesting new natural products found in Penicillium species isolated
from different marine sources and demonstrated the enormous potential of Penicillium and related
common fungi. Later, a detailed analysis of the biodiversity of marine fungi from representative
habitats was undertaken and the metabolite profiles of representative groups, including less abundant
genera were analyzed. The large number of interesting new bioactive compounds found demonstrates
the huge potential of marine fungi that have not been intensively studied so far.
In the following, we will: (i) firstly summarize results on recently discovered new secondary
metabolites of Penicillium species; (ii) then highlight the diversity of fungi in selected marine habitats;
and (iii) give examples of groups of secondary metabolites produced by fungi belonging to a wide
range of genera, including their bioactivities.
2. Secondary Metabolites from Penicillium Species
Though representatives of Penicillium are among the most studied fungi and represent important
drug producers, such as Penicillium chrysogenum (P. chrysogenum) as producer of penicillin and
Penicillium griseofulvum as producer of griseofulvin, it is amazing how many new secondary metabolites
continue to be found within this group of fungi as shown in reviews by Rateb and Ebel [6],
Wang et al. [13] and Blunt et al. [11].
It happened that marine isolates of P. chrysogenum were our first intensively studied fungi,
because they produced sorbicillacton A, which was considered as specifically active against human
leukemia cell lines [14]. The work on P. chrysogenum revealed that in addition to sorbicillacton A and
sorbicillacton B a number of other derivatives of sorbicillin were produced under the conditions applied.
These included sorbicillin, 6-hydroxyoxosorbicillinol, oxosorbicillinol, sorbifuranol, sorbivineton and
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bisvertilonon [14]. Quite interestingly, the well-known product from this species, penicillin was not
among the metabolites found under the applied conditions.
Studies on the biosynthesis and production of sorbicillacton A revealed that the compound was
formed from sorbicillin, alanine and fumaric acid and always a small amount of sorbicillacton B
(a saturated double bond in a side chain is the only structural difference) was formed. In order to
achieve the production of larger amounts of sorbicillacton A, several approaches have been made.
Because of serious problems in separating sorbicillacton A and B using HPLC methods, attempts
were made to modify the culture conditions in such a way, that sorbicillacton A would be the only
product. These attempts failed and always both sorbicillacton A and B were formed at a certain ratio.
In order to increase the yield of sorbicillacton A, a selection of other marine isolates of P. chrysogenum
was studied and, by using various culture media and growth conditions, strains were identified with
strongly increased production rates of sorbicillacton A [1]. Quite interestingly, in addition to the culture
conditions also the treatment of the spore suspensions used as an inoculum for the producing cultures
turned out to be of importance for the production yield of sorbicillacton A. Most probably the history
of the precultures and the treatment of spores have been underestimated in other similar studies. By
choosing the most suitable spore suspension, the most appropriate culture conditions and the best
producer strains, the yield of sorbicillacton A could be increased from initially 2–4 mg/L to more than
500 mg/L (and later even up to 1 g/L) [1]. However, the production was possible only in standing
surface cultures with liquid media, but not in shaken cultures under submersed conditions. At the
end, approximately 100 g of sorbicillacton A could be produced, purified and provided for further
studies [1].
From the same fungus, the structure of sorbifuranone A was elucidated and a biosynthetic
pathway proposed with a furanone as a precursor to become attached to sorbicillinol [15]. This
cillifuranone was identified later in cell extracts of P. chrysogenum, which strongly supported the
proposed biosynthetic pathway of sorbifuranone A [2].
In Penicillium rugulosum, more than 10 different derivatives of a polyene were produced and the
chemical structures of some of these prugosines were determined [3]. These polyenes were typical
polyketides formed from acetyl units and the methyl groups derived from the universal donor of
methyl groups, S-adenosyl-methionine [3]. As they were rather unstable compounds, no detailed
studies have been made regarding their biological activities.
Interesting compounds were also produced by the Penicillium species strain KF620 isolated from
the North Sea and closely related to various Penicillium species (P. verrucosum, P. viridicatum, P. hordei,
P. tricolor, P. alii, P. albocoremium, P. neoechinulatum) with 99% sequence similarity of 18S rRNA and ITS
genes [16]. This strain produced several derivatives of eutypoids with good activity against glycogen
synthase kinase 3β, a target for the treatment of diabetes 2. The eutypoids are unique structures
which do resemble in three-dimensional appearance the synthetic compound 3B-415286 (though both
compounds have significantly different structures), which is the result from a systematic search for a
good inhibitor of GSK-3β [16,17]. Among the four tested eutypoid derivatives produced by the strain,
in particular eutypoid B and C had good inhibitory activity (IC50: <1 µM) against glycogen synthase
kinase 3β, if compared to the synthetic compound SB-415286 (IC50: 90 nM) [16].
These few examples demonstrate that marine isolates of the genus Penicillium still represent a
good source for new and interesting bioactive compounds. It is quite remarkable to see that in all
mentioned examples the producers built several derivatives of structurally related compounds at the
time. Apparently, this is a general phenomenon also seen with other fungi as reviewed by Rateb and
Ebel [6] and also shown in the examples below. This is especially important if one recognizes that the
different derivatives in many cases have different bioactivity profiles and even may specifically act on
a particular target system.
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3. Fungal Diversity in the Marine Environment
Fungi are widely distributed in marine environments from the deep sea to polar ice covers. They
occur in sediments and are found in all kinds of living and dead organic matter. Their numbers in ocean
waters are quite low compared to bacteria and most of the studies on marine fungi have been made
with those associated with marine sediments, with specific substrates like driftwood, algae, corals and
in particular with sponges [2]. Quite a number of investigations have demonstrated that most marine
sponges harbor a wealth of fungi, often with representatives of Acremonium, Aspergillus, Fusarium,
Penicillium, Phoma, and Trichoderma [2,18]. Due to their accumulation within the animal a large number
of fungal species can be isolated from sponges, which increases the probability to find representatives
of less common taxa. For example, fungi belonging to the less common genera Beauveria, Botryosphaeria,
Epicoccum, Tritirachium, and Paraphaeosphaeria have been obtained from marine sponges [5,19,20] and
isolates belonging to Bartalinia and Volutella were obtained from Tethya aurantium [2].
In order to estimate the overall potential of marine fungi for natural product biosynthesis, it is
important to know the phylogenetic diversity of marine fungi, the biosynthetic potential of the species
and strains and the phylogeny of natural products biosynthesis. Therefore, much emphasis has to be
given to the determination of the phylogenetic position of the fungi under investigation in order to
enable correlation of the phylogenetic relationship to secondary metabolite production, respectively,
to the genetic potential of such a production obtained from genomic sequences. Quite a number of
genomic sequences of fungi are currently under way and those completed demonstrate an overall
tremendous biosynthetic capacity of fungi, with commonly about 30 to 40 biosynthetic gene clusters
coding for secondary metabolites in a single genome [21–23]. The majority of these gene clusters have
not yet been correlated to their corresponding natural products, but the consequent analysis of these
data and their correlation with produced metabolites and their biosynthetic pathways will certainly
give a solid background for future phylogenetic considerations of biosynthetic pathways.
The problems related to taxonomy and species identification of marine fungi have a serious
impact on the evaluation of fungal species diversity and in consequence also on the analysis of the
evolution and diversity of biosynthetic pathways of their secondary metabolites. In fact, from a total of
approximately 30 studies on secondary metabolites from fungi of the deep sea, one-third was identified
as belonging to Penicillium, one-third to Aspergillus and the remainder was distributed to different
other genera [13]. The high proportion of members of the genera Penicillium and Aspergillus may
reflect the high abundance of representatives of these two genera in the samples. It causes problems to
estimate the overall diversity of cultured fungi, because the probability to isolate fungi present only in
low abundance is significantly reduced. Furthermore, it is disappointing to see, that only part of the
fungi of these and other studies were identified on a species level. Only one-third of the studies gave
a species name to the isolated fungus [13] and not in all cases this identity must be correct, because
of the difficult assignment to species of fungi in general. For this reason, a number of fungi studied
in respect to natural product biosynthesis remained unidentified at the species level as is depicted in
several reports and reviews (e.g., [2,6,16]).
We have studied the diversity of fungi in the deep Mediterranean Sea and in marine sponges, in
particular in T. aurantium [2] and evaluated the production of natural products from less abundant
fungal genera. A valuable tool for the identification of fungal isolates proved to be the combination of
morphological criteria and the comparison of the ITS1-5.8S-ITS2 fragment sequences, though even
with these solid data, a clear species assignment was not always possible.
Our studies with sediments from the deep Mediterranean Sea indeed showed a dominance
of Aspergillus and Penicillium isolates, which together represented almost half of all 43 isolates [24].
However, in addition, representatives from 10 other genera were found, including several isolates
of Cladosporium and Paecilomyces and single isolates of Acremonium, Auxarthron, Biscogniauxia,
Capnobotryella, Engyodontium, Eutypella, Microascus and Ulcocladium. The results of this study
demonstrate that the majority of the cultured fungal genera are present in minor proportions and
cannot be detected unless the number of isolates, unless the amount of sample used for isolation are
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significantly increased. Thus, a larger number of species and genera present in the studied sediments
probably escaped detection due to the low number of (less than 50) isolates in total.
Consistently, fungi isolated from sponges account for the largest number (28%) of novel
compounds reported from marine fungi [7]. This high proportion may be related to both, the
general interest in sponges as research objects and the abundance of fungi in sponges. In one
of the most detailed studies on the cultured diversity of fungi associated with marine sponges,
a particular high fungal diversity was obtained from T. aurantium and a detailed view on the
isolated fungi revealed the presence of 29 genera among 160 isolates (23 not identified) (Figure 1) [2].
There was no clearly dominant group, either at the level of order or genus. Representatives of the
following orders were isolated: Eurotiales, Microascales, Hypocreales, Xylariales, Heliotiales, Capnodiales,
Pleosporales and Botryosphaerales [2]. Major groups included members of the genera Penicillium (40),
Cladosporium (22), Aspergillus (11), Alternaria (9), Fusarium (9), and Trichoderma (8), but small numbers
also of Acremonium (5), Phoma (4), Eutypa (3), and Bionectria (3) were present. In addition, 19 further
genera (Aureobasidium, Bartalinia, Engyodontium, Epicoccum, Eurotium, Gloetinia, Glomerella, Microdiplodia,
Microdochium, Mucor, Myrothecium, Nectria, Paecilomyces, Petromyces, Peyronellea, Phoma, Pyrenochaeta,
Verticillium, and Volutella) were isolated, but were represented by one or two isolates only [2].
Mar. Drugs 2016, 14, 0000 
5 
interest   sponges as res arch obj cts and the abundance of fungi  in spo es. In one of the most 
detailed studi s on the cultured div rsity of fungi as ociated with marine sponges, a particular high 
fungal diversity was obtained from T. aurantium and a detailed view on the isolated fungi revealed 
the presence of 29 g nera among 160 isolates (23 not identif ed) (Figure 1) [2]. There was no clearly 
dominant gr up, either at the level of order or genus. Representatives of the following ord rs wer  
isolated:  Eurotiales,  Microascales,  Hypocreales,  Xylariales,  Heliotiales,  Capnodial s,  P osporales  nd 
Botryosphaerales [2]. Major g oups included members of th  gen ra Penicillium (40), Cladospor   22  
Aspergillus (11), Alterna ia (9), Fusarium (9),  nd Trichoder a (8), but small nu bers also of Acremonium 
(5), Phoma (4), Eutypa (3), and Bionectria (3) were prese t. In  ddition, 19 further genera (Aureobasidium, 
Bartalinia,  Engyo ontium,  Epicoccum,  Eurotium,  Gloetinia,  Glomerella,  Microdiplodia,  Microdochium  
uc r, Myrothecium, Nectria, Paecilomyces,  etromyces, Peyronellea, Phoma, Pyrenochaeta, Verticillium  
and Vol tell ) were isol ted, but wer  represented by one or two isolates only [2]. 
 







particular with  those genera  that  are more  abundant. The majority of  isolates of Aspergillus  and 
Penicillium as members of the Eurotiales and of Alternaria as member of the Pleosporales quite likely are 






outer  cortex  layer  and  in  the  inner  core part  of  the  sponge. Even more  significant,  the  bacterial 
communities within the two parts of the sponge are different to the exclusion of common sequences 
[25]. This was reason to have a separate view on the fungal community of both the core part and the 
cortex of  this  sponge. An exclusive differentiation as  seen  for  the bacteria  could not be  revealed 
(Figure 2). However, with a total of 85 isolates from the core part and 75 isolates from the cortex, it is 


































. iversity of fungal enera tained fr i i
near Rovinj, with 29 identified gener among 160 isolates (numbers ndicat
the number of stra ns isolated).
Because of the low abundance of many fungal genera, it is obviously necessary to increase the
number of samples processed and of strains isolated to obtain a more complete view of their diversity.
The high diversity seen at the genus level extends further to the subgenus-level. This is visible by the
relatedness of strains in the phylogenetic trees based on sequences of 18S rRNA and ITS genes [2],
in particular with those genera that are more abundant. The majority of isolates of Aspergillus and
Penicillium as members of the Eurotiales and of Alternaria as member of the Pleosporales quite likely are
not identical at the species level. In contrast, isolates of Fusarium, Cladosporium and Trichoderma include
groups of closely related strains quite likely belonging to the same or closely related species [2]. Though
the diversity based on 160 isolates is very high, a view on diversity and abundance of represented
genera makes it very likely that proper attempts to further increase the number of isolates also will
increase the depicted diversity at different taxonomic levels.
A peculiarity of the sponge T. aurantium is the clear distinction of different types of cells in
the outer cortex layer and in the inner core part of the sponge. Even more significant, the bacterial
communities within the two parts of the sponge are different to the exclusion of common sequences [25].
This was reason to have a separate view on the fungal community of both the core part and the cortex
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of this sponge. An exclusive differentiation as seen for the bacteria could not be revealed (Figure 2).
However, with a total of 85 isolates from the core part and 75 isolates from the cortex, it is obvious
that the abundance of Penicillium in the cortex (approximately 16% of all) is much lower compared to
the core part (approximately 33% of all). Though the total number of genera isolated from the two
parts of the sponge were almost identical (21 versus 20), several genera were isolated only from one
of the two compartments: Aureobasidium, Gloeotinia, Microdiplodia, Nectria, Petromyces, Pyrenochaeta,
Verticillium and Volutella were only found in the cortex, while Eurotium, Glomerella, Microdochium, Mucor,
Myrothecium, Paecilomyces, Peyronella, Phoma and Scopulariopsis were only obtained from the core part.
However, because the low number of isolates from these genera (one or two) this result is considered
to point out an incomplete recovery of the diversity in both compartments rather than to demonstrate
clear differences in their composition.
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Figure 2. Diversity of fungal genera isolated from 10 specimen of Tethya aurantium from the
Mediterranean Sea: (a) isolates from the cortex and (b) from the core part (numbers indicate the
number of strains isolated).
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In order to describe the chemical diversity of natural products formed by fungi obtained from
T. aurantium, a selection of the isolates were screened for natural products and bioactive compounds,
and many known metabolites were identified [2], no matter whether the strains were from abundant
or rare genera. Among the described new structures were the scopularides from Scopulariopsis
brevicaulis [26], the chlorazaphilones from Bartalinia robillardoides [27] and the cillifuranone from a
Penicillium strain [2]. In addition, the most potent producer of sorbifuranones A–C was a P. chrysogenum
isolated from T. aurantium [1,15].
4. New Metabolites from Marine Fungi
In order to obtain information on the metabolites produced from a wide range of marine
fungi, we studied representative isolates from a number of different genera including less studied
groups and genera isolated from various marine sources. Among the genera and species studied are
Asteromyces cruciatus [23], Trichoderma sp. MF106 [28], Stachybotrys sp. MF347 [29], Talaromyces sp.
LF458 [30], S. brevicaulis LF580 [26], Calcarisporium sp. KF525 [31,32], B. robillardoides LF550 [27],
Cladosporium sp. KF501 [33], and Massariosphaeria typhicola KF970 [34]. A number of new compounds
and their bioactivities from these studies were reported.
4.1. Trichoderma sp. Strain MF106
Fungi of the genus Trichoderma (order Hypocreales) are widespread in both terrestrial and marine
environments. They are frequently found on decaying wood and in soil, as well as in marine sediments,
marine sponges, and mangrove forests [35]. Marine representatives of the genus Trichoderma produce a
variety of bioactive metabolites, such as the antimycobacterial aminolipopeptide trichoderins [36], the
antifungal trichodermaketone A [35], the cytotoxic dipeptide trichodermamide B [37] and antibacterial
tetrahydroanthraquinone and xanthone derivatives [38,39].
Two unusual pyridones, trichodin A (1) and trichodin B (2), together with pyridoxatin (3) were
produced by the marine Trichoderma sp. strain MF106 from the Greenland Sea [28]. Trichodin B
(2) turned out to be a ribofuranoside of 1 and represented the first example of a pyridone with a
glycosylated mono sesquiterpene (Figure 3).
Trichodin A showed moderate antibiotic activities against Gram-positive bacteria including the
clinical relevant Staphylococcus epidermidis (IC50: 24 µM), but was not active against Trichophyton rubrum.
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known  spirocyclic drimanes  such  as  stachybocin A  (15)  and  stachybocin B  (14)  featured by  two 
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Figure 3. Chemical structures of compounds 1–3.
4.2. Stachybotrys sp. Strain MF347
The genus Stachybotrys (order Hypocreales) comprises approximately 100 species [40] and marine
isolates have been obtained from various marine environments such as the rhizosphere of mangroves,
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mud of the intertidal zone, intertidal pools, brackish waters, marine sediments and sponges, marine
algae, and sea fans [29,41].
A major class of secondary metabolites produced by Stachybotrys species, including isolates of
S. chartarum obtained from habitats around the world is represented by spirocyclic drimanes [42]. Altogether
13 structurally and biosynthetically related compounds were identified in Stachybotrys sp. strain MF347
isolated from marine driftwood [29] (Figure 4). This fungus produced a number of known spirocyclic
drimanes such as stachybocin A (15) and stachybocin B (14) featured by two sesquiterpene-spirobenzofuran
structural units connected by a lysine residue, chartarlactam O (13), chartarlactam K (5), F1839A (6),
stachybotrylactam (7), stachybotramide (8), and 2α-acetoxystachybotrylactam acetate (9), as well as the
sesquiterpene ilicicolin B (16). The most conspicuous new metabolites of this strain were the spirocyclic
drimanes stachyin A (4) and stachyin B (10) [29].
Quite a number of different biological activities are associated with spirocyclic drimanes, including
immune-suppressive activity [43], endothelin receptor antagonistic activity [44], and inhibition of
tyrosine kinase [45]. Clear differences were obtained in the bioactivities of spirocyclic drimanes with
two and those with one sesquiterpene-spirobenzofuran structural units. While the spirocyclic drimanes
of the first group (10, 14 and 15) showed antibacterial activity against Gram-positive bacteria, including
the clinically relevant methicillin-resistant Staphylococcus aureus (MRSA), those of the second group
with one sesquiterpene-spirobenzofuran structural unit (compounds 4–9 and 11–13) exhibited no
activities [29]. Cytotoxic activity (IC50: 13–14 µM) was specifically found for stachyin B (10) only [29].
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Figure 4. Chemical structures of compounds 4–16.
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4.3. Talaromyces sp. Strain LF458
Talaromyces funiculosum (order Eurotiales) has a world-wide distribution and is common in all
climatic zones with the possible exception of extreme cold habitats. It has frequently been isolated from
various habitats, including estuarine sediments, salt marshes and a mangrove swamps [46]. A fungus
isolated from the marine sponge Axinella verrucosa and tentatively classified as a T. funiculosum strain
LF458 was investigated and found to produce several polycyclic compounds with common motifs.
T. funiculosum is known as producer of a number of bioactive compounds [30], such as the
approved drug lovastatin, which inhibits the HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A)
reductase, an important enzyme in the biosynthesis of cholesterol [47]. In addition, secalonic acid D, a
compound with cytotoxic activity, 11-desacetoxy-wortmannin, a fungicidal and anti-inflammatory
metabolite, and helenin, being active against the swine influenza virus, were identified [48–50]. Further
metabolites isolated from this fungus include mycophenolic acid, patulin, and 3-O-methylfunicone,
which inhibit the growth of the fungus Rhizoctonia solani which is pathogenic to tobacco [51]. The
closely related species Talaromyces pinophilum is producer of the antibacterial pinodiketopiperazine A
and 6,7-dihydroxy-3-methoxy-3-methyl phthalide, which also exhibit lethal activity to brine shrimp
Artemia salina [52]. Notable is that during co-cultivation of T. pinophilum with Trichoderma harzianum
the production of the Talaromyces metabolites secopenicillide C, penicillide, MC-141, pestalasin A, and
stromemycin were enhanced [53].
In addition to two new oxaphenalenone dimers talaromycesone A (17) and talaromycesone
B (18) and the new isopentenyl xanthenone talaroxanthenone (19), six diphenyl ether derivatives
(∆1
1,31 ,-11-dehydroxypenicillide (20), 11,21-dehydropenicillide (21), vermixocin A (22), vermixocin B (23),
31-methoxy-1121-dehydropenicillide (24) and AS-186c (25)) were identified in extracts from Talaromyces
sp. strain LF458 (Figure 5).
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Figure 5. Chemical structures of compounds 17–25.
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Oxaphenalenones were isolated mainly from representatives of the genera Talaromyces,
Penicillium, and Coniothyrium [54,55], including the antibacterial bacillosporins A–C from Talaromyces
bacillisporus [54], the antibacterial and cytotoxic conioscleroderolide from Coniothyrium cereal [55],
and erabulenols A and B from the Penicillium sp. FO-5637, which inhibit the cholesteryl ester
transfer protein [56]. While oxaphenalenones have been previously obtained from Talaromyces species,
talaromycesone B (18) represents the first 1-nor oxaphenalenone dimer carbon skeleton from a natural
source. It should be noted, that, although Cao et al. [57] determined an S-configuration at C-91 and
made a generalizing conclusion that duclauxin and its analogues have this S-configuration, such a
generalization is problematic and biosynthetically both epimers may be formed. This has to be taken
into consideration with the structures of talaromycesone A and B (17 and 18).
The first oxaphenalenone with acetylcholinesterase inhibitory activity is represented by
talaromycesone A (17). Also talaroxanthenone (19), and AS-186c (25) inhibited the activity of
acetylcholinesterase (IC50: 1.6 µM to 2.6 µM) and these two compounds inhibited phosphodiesterase
PDE-4B2 (IC50: 2.6–7.3 µM) in addition, but did not have antimicrobial or significant cytotoxic
effects [30]. Compounds 17 and 25 also exhibited good antibacterial activities with IC50 values
of 3.70 µM and 1.34 µM against human pathogenic Staphylococcus strains.
As new or more effective molecules for the treatment of Alzheimer’s disease are urgently needed,
because the cases of this disease are expected to dramatically increase over the coming decades,
compounds such as 17, 19 and 25 are important as possible candidate molecules for drug development
to treat neurological disorders. Their special advantage is the lack of cytotoxic properties. In addition,
some of these molecules may have antibiotic properties (compounds 17 and 25) against pathogenic
bacteria [30].
4.4. Calcarisporium sp. Strain KF525
Fungal species of the genus Calcarisporium (order Hypocreales) have a widespread occurrence and
are frequently found as mycoparasites or symbionts of higher basidomycetes and ascomycetes [58–62].
Among the natural products that have been described from this genus are antifungal compounds like
15-azahomosterols, aurovertins inhibiting the mitochondrial ATPases, and calcarisporins B1–B4 with
calcarisporin B1 showing cytotoxic activity as discussed by Silber et al. [31].
An isolate from the German Wadden Sea, Calcarisporium sp. strain KF525, showed a diverse
chemical profile, including three calcaripeptides, cyclodepsipeptides with highly common structural
motifs [31] and ten structurally closely related linear and macrocyclic polyesters of the 15G256 group
(15G256α, α-2, β, β-2 and pi, 26–30) and related (methylated) calcarides A–E (31–35) (Figure 6) [32]. The
15G256-type compounds are known as metabolites from a number of fungi, of ascomycetes (Hypoxylon,
Penicillium, Talaromyces, Acremonium and Scedosporium species) as well as of the basidiomycete
Albatrellus confluens [63–68].
Biological activities assigned to the 15G256 agents include antifungal, estrogenic and cytotoxic
properties. They were also shown to potentiate nerve growth factor-induced neurite outgrowth.
Compounds 15G256α (26) and β (27) for example attracted attention in the field of crop protection, as
they displayed antifungal properties against the important plant pathogenic fungi, Botrytis cinerea and
Monilinia fructigena [64].
The 15G256 compounds and the methylated derivatives thereof were found to display
antibacterial activities with a clear structure-activity relationship [32]. Slight structural variation
by methylation had significant influence on this activity. All macrocyclic compounds (26, 27, 31–33)
inhibited S. epidermidis and Xanthomonas campestris, while the linear polyesters did not [32], indicating
that the ring structure is required for this activity. Similar observations have been made for antifungal
properties of the 15G256 compounds [63]. Although low to moderate antibiotic activity against
S. epidermidis and X. campestris was associated with several of these compounds, a strongly reduced
activity against S. epidermidis (but not against X. campestris) was found with the methylated analogs,
and the strongest inhibition against S. epidermidis was exhibited by 15G256α (26) (MIC 13 µM). Good
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inhibitory activity against the Xanthomonas was restricted to the methylated calcaride A (31) (IC50:
6 µM) and inhibition of Propionibacterium acne was exhibited only by the non-methylated 15G256pi (30)
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Figure 6. Chemical structures of compounds 26–35.
4.5. Bartalinia robillardoides Strain LF550
The genus Bartalinia (order Xylariales) is rare among marine fungi and also is a rare genus among
the isolates from the Mediterranean sponge T. aurantium [2]. B. robillardoides is known as a producer of
taxol, an anticancer drug in clinical application [69].
B. robillardoides strain LF550 produced a number of secondary metabolites belonging to the
chloroazaphilones. In addition to the known helicusin A (36) [70] and deacetylsclerotiorin (37) [71],
three new chloroazaphilones, helicusin E (38), isochromophilone X (39) and isochromophilone XI (40),
were identified (Figure 7) [27].
Though azaphilones represent a widespread family of fungal pigments and more than 170 azaphilones
are produced by 23 different genera from 13 fungal families [72], they were for the first time described
from the genus Bartalinia by Jansen et al. [27]. In particular the chlorinated congeners are less common
and these have been found so far in representatives of Penicillium, Chaetomium, Emericella, Talaromyces and
Fusarium [72].
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Figure 7. Chemical structures of compounds 36–40.
Despite their structural similarities, the chlorazaphilones produced by this fungus revealed
different biological activity spectra against a test panel of four bacteria, three fungi, two tumor cell
lines and two enzymes [27]. Weak antibacterial activities were found against Bacillus subtilis and
Staphylococcus lentus for compounds 37 and 40. Antifungal activities (Candida albicans, Trichophyton
rubrum and Septoria tritici) were found for deacetylsclerotiorin (37) (IC50: 2–10 µM) and for helicusin A
(36), but not for helicusin E (38) and the methylester of helicusin A [27]. Most significant inhibition
of acetylcholinesterase was associated with helicusin A (36) (IC50: 2.1 µM) and of phosphodiesterase
PDE4 with deacetylsclerotiorin (37) (IC50: 2.8 µM) [27]. Interestingly, none of these compounds showed
cytotoxic activity.
4.6. Cladosporium sp. Strain KF501
The genus Cladosporium (order Capnodiales) represents one of the largest and most heterogeneous
fungal genera [73] with ubiquitous occurrence, including marine habitats. Cladosporium sp. strain KF501
was isolated from the German Wadden Sea and according to ITS sequence similarities was identical
(100% similarity) to Cladosporium cladosporioides, C. pseudocladosporioides, C. uredinicola, C. bruhnei and
C. colombiae. Hence, strain KF501 could be clearly identified as a member of the genus Cladosporium,
but identification to the species level could not be achieved [33].
Cladosporium species have been shown to produce a variety of natural products, such as the
melanins which are giving the fungal colonies their typical colored appearance, the antifungal
cladosporides [74,75], the plant growth factors cotylenins [76,77], calphostins which specifically inhibit
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the protein kinase C [78], and cladosporin exhibiting a broad activity spectrum including antifungal,
antibacterial, insecticidal, phytotoxic and immunosuppressive properties [79–83].
Malettinins are tropolone/dihydropyran ring structures and are unique with regard to their
linkage to a furan ring. Originally, malettinins A–C and malettinin D were reported from an
unidentified fungus [84,85] and for the first time Cladosporium sp. strain KF501 was shown to produce
malettinins A–C (41–43) and the new malettinin E (44), which is the 13-epimer of malettinin C (43)
(Figure 8) [33]. Malettinin D was not found [33].
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Malettinins A–C (41–43) displayed weak inhibitory properties against C. albicans, B. subtilis and
S. aureus and malettinin A inhibited Aspergillus flavus and Fusarium verticillioides in addition [84].
Higher activities were found against the bacterium X. campestris and the fungus T. rubrum [33]. A clear
influence of the chemical structure and of configurational changes on biological activities was observed.
All stereoisomeric compounds (42–44) inhibited X. campestris in comparable concentration ranges,
while 41, possessing a very slightly modified furan ring, did not show inhibition. Consequently, it was
suggested that the furan ring structure is critical for antibacterial properties of the malettinins against
X. campestris [33]. In addition, activities against T. rubrum apparently are sensitive to configurational
changes of the malettinins because the stereoisomers of the malettinins exhibited different IC50
values [33].
4.7. Massariosphaeria typhicola Strain KF970
Lindgomycetaceae (order Pleosporales) represent a less studied fungal group. Members of the
Lindgomycetaceae were isolated from submerged parts of decaying wood and plant material in
freshwater environments. Little is known on the metabolic capabilities of Lindgomycetes and related
fungi and on their production of bioactive compounds.
Two fungi of the family Lindgomycetaceae, strains KF970 and LF327, were isolated from marine
habitats of the Baltic Sea and the Arctic Ocean and were identified on the basis of 18S rRNA gene
sequences. These were highly similar to each other and to M. typhicola (99.9% for KF970 and 99.5% for
LF327) [34]. Therefore, both isolates can be regarded as strains of this species.
Although both strains originated from different geographic regions, they produced the same
metabolites. Two unusual antibiotic polyketides, lindgomycin (45) [34] and ascosetin (46) [86], were
identified (Figure 9). They contain two distinct structural domains, a bicyclic hydrocarbon and
a tetramic acid, which are connected by a bridging carbonyl. Naturally occurring tetramic acid
derivatives originating from a variety of marine and terrestrial fungi have attracted a great deal of
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interest due to their broad-spectrum biological activities and challenging structural complexity [87,88].
The majority of the compounds isolated to date exhibited antibiotic or antiviral activity. Tetramic acids
possessing an octahydronaphthalene skeleton also are active against Gram-positive bacteria but are
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Lindgomycin (45) and ascosetin (46) revealed good antibiotic activity against a number of
Gram-positive bacteria (IC50: 2–6 µM), the yeast C. albicans and the fungus S. tritici (IC50: 5–10 µM) [34].
Both compounds showed antibiotic activities against methicillin resistant S. aureus with IC50 values of
5.1 µM and 3.2 µM, respectively. The causative agents of black rot in crucifers (e.g., cabbage) and of leaf
spot disease on crops (e.g., wheat), X. campestris and S. tritici, were also inhibited by the two compounds.
No inhibition of Gram-negative bacteria was observed [34]. The lack of activity against Gram-negative
bacteria already has been noticed for other tetramic acid derivatives [89] and maybe related to the
difference in the cell wall structures. Apparently the outer membrane of Gram-negative bacteria is an
efficient permeability barrier for these molecules.
5. Conclusions
The marine sponge T. aurantium, taken as a representative example of a suitable habitat for marine
fungi, gives rise to assume that the fungal diversity in marine habitats is much larger than anticipated
from those fungi studied so far in regard to the production of natural products. Due to the normally
low number of fungi in marine habitats (compared to bacteria), however, it requires special effort to
isolate a larger number of fungi from a particular sample. This in turn is necessary to adequately
depict the natural diversity among the cultured strains. Nonetheless, the frequency of finding new
secondary metabolites from marine fungi remains high. In addition, the following few key statements
highlight the attractiveness of marine fungi as research object to search for new natural products.
- Despite the fact that natural products from some fungal genera, in particular Penicillium and
Aspergillus, have been often and intensively studied, there is still a great potential of secondary
metabolites produced by these fungi, which has not yet been fully explored.
- Much of the fungal diversity and the large potential of secondary metabolites of the untapped
diversity of fungi in the marine environment still is to be discovered.
- Much of the genomic/genetic potential of secondary metabolites of cultured fungi is not produced
under standard culture conditions. In particular, changes in media and culture conditions often
change the metabolite profiles and are likely to increase the number of known products from the
fungi. In addition, other methods such as cocultivation with other fungi or bacteria or the use of
epigenetic modulators may stimulate biosynthesis of the “hidden genomic potential”.
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- It has been demonstrated that the production of “families“ of secondary metabolites of structurally
related derivatives, which often reveal significant differences in bioactivities, is common to many
fungi. Because already small structural changes can be highly effective in regard to the bioactivity,
it is important to study the full spectrum of structural variation offered by the fungi in order to
unravel their biotechnological potential.
For improved success in future studies on secondary metabolites of marine fungi, the following
points appear of primary importance:
- The multitude of natural derivatives of individual fungi and their bioactivities should be
carefully explored.
- Biosynthetic pathways and their regulation need to be studied to conclude on explanations for
the formation of multiple derivatives.
- The evolution of biosynthetic pathways of secondary metabolites should be systematically
explored in respect to the presence of new biosynthetic gene clusters, in particular by use of the
growing resource of fungal genome sequences.
- Genus- and species-specific metabolite profiles need to be elaborated using metabolomic and
genomic approaches.
If these approaches and strategies are systematically applied to the search for secondary
metabolites from cultures of marine fungi, we expect to receive a full treasure box of new bioactive
natural products, some of which may qualify as excellent candidates for drug development.
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